J. M. C. Bull

1.1k total citations
43 papers, 842 citations indexed

About

J. M. C. Bull is a scholar working on Biomedical Engineering, Critical Care and Intensive Care Medicine and Oncology. According to data from OpenAlex, J. M. C. Bull has authored 43 papers receiving a total of 842 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Biomedical Engineering, 9 papers in Critical Care and Intensive Care Medicine and 9 papers in Oncology. Recurrent topics in J. M. C. Bull's work include Ultrasound and Hyperthermia Applications (17 papers), Thermal Regulation in Medicine (9 papers) and Nanoparticle-Based Drug Delivery (5 papers). J. M. C. Bull is often cited by papers focused on Ultrasound and Hyperthermia Applications (17 papers), Thermal Regulation in Medicine (9 papers) and Nanoparticle-Based Drug Delivery (5 papers). J. M. C. Bull collaborates with scholars based in United States, Japan and Netherlands. J. M. C. Bull's co-authors include F. R. Strebel, L. Clifton Stephens, David Eric Lees, William H. Schuette, J. Wondergem, Masato Makino, L Danhauser, Paul P. Carbone, Tetsuya Kaneko and Zahid H. Siddik and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

J. M. C. Bull

42 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. M. C. Bull United States 19 252 192 189 149 129 43 842
Mario Feola United States 17 123 0.5× 201 1.0× 207 1.1× 38 0.3× 34 0.3× 58 870
D. Seiffge Germany 14 105 0.4× 344 1.8× 193 1.0× 23 0.2× 69 0.5× 48 1.1k
Kazuaki Asaishi Japan 12 89 0.4× 238 1.2× 81 0.4× 55 0.4× 144 1.1× 41 795
Robert M. DePhilip United States 18 64 0.3× 318 1.7× 33 0.2× 88 0.6× 48 0.4× 31 751
Christopher R. Neal United Kingdom 17 55 0.2× 413 2.2× 77 0.4× 169 1.1× 101 0.8× 26 1.0k
Robert R. Rigor United States 15 69 0.3× 484 2.5× 124 0.7× 40 0.3× 123 1.0× 29 1.0k
Nobuo Yoshimoto Japan 22 167 0.7× 496 2.6× 127 0.7× 5 0.0× 63 0.5× 74 1.3k
Maria Fragiadaki United Kingdom 15 48 0.2× 591 3.1× 87 0.5× 19 0.1× 97 0.8× 27 1.3k
Tadashi Kikuchi Japan 9 70 0.3× 177 0.9× 154 0.8× 19 0.1× 81 0.6× 15 740
Pierre Labrude France 17 85 0.3× 375 2.0× 234 1.2× 70 0.5× 15 0.1× 116 1.0k

Countries citing papers authored by J. M. C. Bull

Since Specialization
Citations

This map shows the geographic impact of J. M. C. Bull's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. M. C. Bull with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. M. C. Bull more than expected).

Fields of papers citing papers by J. M. C. Bull

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. M. C. Bull. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. M. C. Bull. The network helps show where J. M. C. Bull may publish in the future.

Co-authorship network of co-authors of J. M. C. Bull

This figure shows the co-authorship network connecting the top 25 collaborators of J. M. C. Bull. A scholar is included among the top collaborators of J. M. C. Bull based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. M. C. Bull. J. M. C. Bull is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McCarthy, Nicole, Frances Boyle, Nicholas Zdenkowski, et al.. (2014). Neoadjuvant chemotherapy with sequential anthracycline–docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast. 23(2). 142–151. 5 indexed citations
2.
Strebel, F. R., et al.. (2003). The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. International Journal of Hyperthermia. 19(2). 103–118. 18 indexed citations
3.
Berry, James M., et al.. (1997). The use of esmolol in whole-body hyperthermia: Cardiovascular effects. International Journal of Hyperthermia. 13(3). 261–268. 6 indexed citations
4.
5.
Kaneko, Toyozo, et al.. (1997). Optimal duration of whole body hyperthermia when combined with cis-diaminne-1,1-cychlobutane dicarboxylate platinum (II) (carboplatin).. PubMed. 17(3C). 1897–901. 2 indexed citations
6.
Makino, Masato, Robert F. Lodato, L. Clifton Stephens, et al.. (1996). Protective effect of NG-monomethyl-L-arginine against hypotension inducted by combined tumour necrosis factor-α and whole body hyperthermia in rats. International Journal of Hyperthermia. 12(5). 617–634. 2 indexed citations
7.
Wondergem, J., F. R. Strebel, L. Clifton Stephens, Zahid H. Siddik, & J. M. C. Bull. (1995). Chronic effect of whole-body hyperthermia combined simultaneously with cis-diamminedichloroplatinum (II) on normal tissue in rat. International Journal of Hyperthermia. 11(1). 37–47. 5 indexed citations
8.
Ohno, Shinji, et al.. (1993). Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. British Journal of Cancer. 68(3). 469–474. 19 indexed citations
9.
Bull, J. M. C., et al.. (1992). Chemotherapy resistant sarcoma treated with whole body hyperthermia (WBH) combined with 1-3-Bis(2-chloroethyl)-1-nitrosourea (BCNU). International Journal of Hyperthermia. 8(3). 297–304. 13 indexed citations
10.
Wondergem, J., Ruth Ellen Bulger, Zahid H. Siddik, et al.. (1989). A comparison of thermal enhancement of cis-diamminedichloro-platinum (II) induced renal and intestinal toxicities by whole body hyperthermia in the rat. International Journal of Radiation Oncology*Biology*Physics. 16(6). 1551–1556. 11 indexed citations
11.
Bull, J. M. C., et al.. (1988). o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.. PubMed. 48(8). 2239–44. 19 indexed citations
12.
Tonnesen, Alan S., et al.. (1987). Sweating, hemodynamic responses, and thermal equilibration during hyperthermia in humans. Journal of Applied Physiology. 62(4). 1596–1602. 23 indexed citations
13.
Bull, J. M. C., et al.. (1987). SERUM CREATININE CONCENTRATION AND CLEARANCE DURING WHOLE BODY HYPERTHERMIA (≥41.5° C) UNDER GENERAL ANESTHESIA. Anesthesiology. 67(3). A306–A306. 1 indexed citations
14.
Bourke, David, et al.. (1985). CARDIOVASCULAR EFFECTS OF WHOLE BODY HYPERTHERMIA (WBH) (≥ 41.5 °C) DURING GENERAL ANESTHESIA. Anesthesiology. 63(Supplement). A1–A1. 1 indexed citations
15.
Lees, David Eric, et al.. (1982). Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.. PubMed. 65(11-12). 1103–4. 1 indexed citations
16.
Lees, David Eric, et al.. (1979). An Evaluation of Liquid-Crystal Thermometry as a Screening Device for Intraoperative Hyperthermia. Survey of Anesthesiology. 23(6). 364–364. 21 indexed citations
17.
Tormey, Douglas C., et al.. (1976). Evaluation of tamoxifen dose in advanced breast cancer. 17. 8 indexed citations
18.
Bull, J. M. C. & Jane R. MacKinnon. (1975). Phenylbutazone and anticoagulant control.. PubMed. 215(1290). 767–69. 4 indexed citations
19.
Bull, J. M. C., et al.. (1973). Serial In Vitro Bone Marrow Culture in Acute Lymphocytic Leukemia. Blood. 42(5). 687–699. 26 indexed citations
20.
Bull, J. M. C., et al.. (1972). CYTOGENETICALLY ABNORMAL CELL S IN VITRO IN ACUTE LEUKÆMIA. The Lancet. 299(7753). 715–718. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario Feola Breakdown of academic impact, for papers by D. Seiffge Breakdown of academic impact, for papers by Kazuaki Asaishi Breakdown of academic impact, for papers by Robert M. DePhilip Breakdown of academic impact, for papers by Christopher R. Neal Breakdown of academic impact, for papers by Robert R. Rigor Breakdown of academic impact, for papers by Nobuo Yoshimoto Breakdown of academic impact, for papers by Maria Fragiadaki Breakdown of academic impact, for papers by Tadashi Kikuchi Breakdown of academic impact, for papers by Pierre Labrude
Rankless by CCL
2026